Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.34 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19810261 | 0.92 | LTB4R (0.36) | ADORA2BADORA2APNPLTB4RTSHR | |
| SCHEMBL27213500 | 0.91 | ADORA2B (0.35) | ADORA2BADORA2ATSHRALDH1A1LMNA | |
| SCHEMBL21751325 | 0.90 | PLA2G7 (0.33) | ADORA2BADORA2APNPALDH1A1LMNA | |
| SCHEMBL21751403 | 0.90 | ALDH1A1 (0.34) | ADORA2BADORA2ATSHRALDH1A1LMNA | |
| SCHEMBL21751410 | 0.90 | ADORA2B (0.37) | ADORA2BADORA2APNPLTB4RTSHR | |
| SCHEMBL25760333 | 0.90 | ADORA2B (0.37) | ADORA2BADORA2ATSHRALDH1A1LMNA | |
| SCHEMBL21751330 | 0.90 | ADORA2A (0.36) | ADORA2BADORA2APNP | |
| SCHEMBL21751328 | 0.88 | LTB4R (0.36) | LTB4R | |
| SCHEMBL20543457 | 0.88 | ADORA2B (0.36) | ADORA2BADORA2ATSHRALDH1A1LMNA | |
| SCHEMBL30110598 | 0.88 | ADORA2B (0.36) | ADORA2BADORA2ATSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250264464-A1 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING BIOLUMINESCENCE | PROMEGA CORPORATION | 2025-08-21 | — | — | US | disclosed |
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-119955899-A | Compositions, methods and kits for stabilizing coelenterazine and analogs and derivatives thereof | 普洛麦格公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-112996923-B | Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof | 普洛麦格公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-11534504-B2 | Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof | PROMEGA CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534504-B2 | Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof | PROMEGA CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3861128-A2 | COMPOSITIONS AND METHODS FOR STABILIZING COELENTERAZINE AND ANALOGS AND DERIVATIVES THEREOF | Promega Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3841173-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20200386748-A1 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING BIOLUMINESCENCE | PROMEGA CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-20200386748-A1 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING BIOLUMINESCENCE | PROMEGA CORPORATION | 2020-12-10 | — | — | US | disclosed |
| WO-2020210658-A1 | COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING BIOLUMINESCENCE | PROMEGA CORPORATION (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200109146-A1 | COMPOSITIONS AND METHODS FOR STABILIZING COELENTERAZINE AND ANALOGS AND DERIVATIVES THEREOF | PROMEGA CORPORATION | 2020-04-09 | — | — | US | disclosed |
| WO-2020072775-A2 | COMPOSITIONS AND METHODS FOR STABILIZING COELENTERAZINE AND ANALOGS AND DERIVATIVES THEREOF | PROMEGA CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| WO-2020041579-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | ADORA2B 3105/4885ADORA2A 1970/4885PNP 1002/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | ADORA2B 3105/4885ADORA2A 1970/4885PNP 1002/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | ADORA2B 3105/4885ADORA2A 1970/4885PNP 1002/4885 |
| US-20200109146-A1 | COMPOSITIONS AND METHODS FOR STABILIZING COELENTERAZINE AND ANALOGS AND DERIVATIVES THEREOF | SI, CHLSN, APC | ADORA2B 3963/4885ADORA2A 1444/4885PNP 1475/4885 |
| US-11534504-B2 | Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof | SI, CHLSN, APC | ADORA2B 3963/4885ADORA2A 1444/4885PNP 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.